ADVFN ADVFN

Hot Features

Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Knight Therapeutics Inc

Knight Therapeutics Inc (GUD)

8,42
0,11
( 1,32% )
Mis à jour : 16:12:23

Knight Therapeutics Inc (GUD) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
8,42
( 1,32% )
Prix Achat
8,41
Prix Vente
8,45
Volume échangé
5 908
8,31 Fourchette du Jour 8,49
5,66 Plage de 52 semaines 8,90
Cap du marché
Clôture Veille
8,31
Ouverture
8,31
Dernière Transaction
100
@
8.44
Dernière heure de transaction
16:16:09
Volume financier
-
VWAP
-
Volume moyen (3 m)
$ 85 450
Actions en circulation
98 179 361
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
144,92
Bénéfice par action (BPA)
0,06
Chiffre d'affairess (LTM)
510,45M
Bénéfice net (LTM)
5,61M

À propos de Knight Therapeutics Inc

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma... Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Site Web
Siège social
Montreal, Canada
Fondé
2026
Knight Therapeutics Inc est coté dans le secteur Healthcare de la Toronto Stock Exchange avec le ticker GUD. Le dernier cours de clôture d'Knight Therapeutics était de $8,31. Au cours de la dernière année, les actions de Knight Therapeutics ont été négociées dans une fourchette de prix de $ 5,66 à $ 8,90.

Knight Therapeutics compte actuellement 98 179 361 actions en circulation. La capitalisation boursière d'Knight Therapeutics est de $826,67 million. Knight Therapeutics a un ratio cours/bénéfice (ratio PE) de 144.92.

GUD Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.364.466501240698.068.497.88894978.17692075CS
40.425.2588.97.841104918.40957867CS
122.2336.02584814226.198.96.04895787.59492385CS
262.3839.40397350996.048.95.66890066.82338618CS
522.6245.17241379315.88.95.66736346.54314817CS
1563.5773.60824742274.858.94.35711285.80462716CS
2603.1359.1682419665.298.94.281217635.46144935CS

GUD - Frequently Asked Questions (FAQ)

What is the current Knight Therapeutics Inc share price?
The current share price of Knight Therapeutics Inc is $ 8,42
How many Knight Therapeutics Inc shares are in issue?
Knight Therapeutics Inc has 98 179 361 shares in issue
What is the market cap of Knight Therapeutics Inc?
The market capitalisation of Knight Therapeutics Inc is CAD 826,67M
What is the 1 year trading range for Knight Therapeutics Inc share price?
Knight Therapeutics Inc has traded in the range of $ 5,66 to $ 8,90 during the past year
What is the PE ratio of Knight Therapeutics Inc?
The price to earnings ratio of Knight Therapeutics Inc is 144,92
What is the cash to sales ratio of Knight Therapeutics Inc?
The cash to sales ratio of Knight Therapeutics Inc is 1,58
What is the registered address of Knight Therapeutics Inc?
The registered address for Knight Therapeutics Inc is 100 Boul. Alexis-Nihon, Montreal, Quebec, H4M 2P2
What is the Knight Therapeutics Inc website address?
The website address for Knight Therapeutics Inc is www.knighttx.com
Which industry sector does Knight Therapeutics Inc operate in?
Knight Therapeutics Inc operates in the Pharmaceuticals sector

GUD Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock